TY - JOUR
T1 - Tumefactive fibroinflammatory lesion successfully treated with Rituximab
AU - Bishop, Jessica L.
AU - Bryan, Locke Johnson
AU - Savage, Natasha Marie
AU - Byrd, J. Kenneth
N1 - Publisher Copyright:
© 2019 International Advancement Center for Medicine and Health Research. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Skull base pseudotumors, or tumefactive fibroinflammatory lesions (TFIL), are tumors characterized by local destruction with benign histopathology. Treatment includes surgery and steroids with varying degrees of symptom relief. A 45-year-old female presented with right otorrhea and middle ear effusion, which progressed to CN V3 pain/numbness, trismus, headache, and autophony. MRI showed a diffuse infiltrating mass in the right infratemporal region involving the trigeminal ganglion. Biopsy revealed benign fibromuscular and adipose tissue with lymphoplasmacytic infiltrate, giving a diagnosis of TFIL. Resection would be very difficult given tumor location. Initial treatment included an extended course of steroids without response, and interval disease progression. Two courses of rituximab 375 mg/m2 weekly × 4 given 3 months apart were then completed with excellent tolerance. With sixteen months following induction, the patient reports minimal symptoms with radiographic findings confirming continued disease regression. Rituximab is a potential treatment option for patients with TFIL without response to steroids.
AB - Skull base pseudotumors, or tumefactive fibroinflammatory lesions (TFIL), are tumors characterized by local destruction with benign histopathology. Treatment includes surgery and steroids with varying degrees of symptom relief. A 45-year-old female presented with right otorrhea and middle ear effusion, which progressed to CN V3 pain/numbness, trismus, headache, and autophony. MRI showed a diffuse infiltrating mass in the right infratemporal region involving the trigeminal ganglion. Biopsy revealed benign fibromuscular and adipose tissue with lymphoplasmacytic infiltrate, giving a diagnosis of TFIL. Resection would be very difficult given tumor location. Initial treatment included an extended course of steroids without response, and interval disease progression. Two courses of rituximab 375 mg/m2 weekly × 4 given 3 months apart were then completed with excellent tolerance. With sixteen months following induction, the patient reports minimal symptoms with radiographic findings confirming continued disease regression. Rituximab is a potential treatment option for patients with TFIL without response to steroids.
KW - Immunomodulators
KW - Inflammatory pseudotumors
KW - Pseudotumor
KW - Rituximab
KW - Tumefactive fibroinflammatory lesion
UR - http://www.scopus.com/inward/record.url?scp=85067495208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067495208&partnerID=8YFLogxK
U2 - 10.5582/irdr.2019.01061
DO - 10.5582/irdr.2019.01061
M3 - Article
AN - SCOPUS:85067495208
SN - 2186-3644
VL - 8
SP - 138
EP - 141
JO - Intractable and Rare Diseases Research
JF - Intractable and Rare Diseases Research
IS - 2
ER -